Global Cell-Free Protein Expression Market, by Product Type (E. coli Cell-free Protein Expression System, Rabbit Reticulocytes Cell-free Protein Expression System, Wheat Germ Cell-free Protein Expression System, Insect Cells Cell-free Protein Expression System, Mammalian Cell-free Protein Expression System, Labelling Tags, and Others {Vectors, yeast cell extracts, among others}), by Expression Mode (Continuous flow Expression, and Batch Expression), by Application (Enzyme Engineering, Protein Labeling, Protein-Protein interaction, Protein Purification, and Others {High Throughput Production, among others}), by End User (Biotechnological Companies, Pharmaceutical Companies, Contract Research Organizations, and Academic/ Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 280.2 million in 2022 and is expected to exhibit a CAGR of 6.4% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key players operating in market are focusing on rapid research and development activities for launch of new cell-free protein expression, which is expected to drive the global Cell-Free Protein Expression Market growth over the forecast period.
For instance, in April, 2022, Creative Biolabs, a U.S.-based biotechnology company, announced the launch of an advanced platform for membrane protein production and anti-membrane protein antibody discovery named Magic. Magic membrane protein platform includes services such as: Cell-based Membrane Protein Expression and Purification, Cell-free Membrane Protein Expression and Purification, Membrane Protein Solubilization and Stabilization, and others.
Global Cell-Free Protein Expression Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 523 million cases and 6.3 million deaths due to Coronavirus (COVID-19) were reported up till June 5, 2022, across the globe.
The COVID-19 pandemic has adversely affected several markets across the globe. Lockdowns in various countries have placed an economic burden on the private healthcare sector. Healthcare providers are facing challenges in terms of availability of manpower, equipment, consumables, and other resources to ensure safe treatment of patients with other diseases, and declining outpatient visits among others.
However, the COVID-19 pandemic had a positive impact on the Cell-Free Protein Expression Market due to its potential use as an inexpensive and fast diagnostic tool for the COVID-19. During the early days of COVID-19 pandemic, the use of efficient and rapid diagnostic tools became very important. During this period, cell-free protein expression (CFPS) platforms emerged as attractive tools for fast and inexpensive diagnosis of the virus.
For instance, in June 2021, a team of researchers from Harvard University's Wyss Institute for Biologically Inspired Engineering and the Massachusetts Institute of Technology discovered a way to embed synthetic biology reactions into fabrics, creating wearable biosensors that can be customized to detect pathogens and toxins and alert the wearer. The team had integrated this technology into standard face masks to detect the presence of the SARS-CoV-2 virus in a patient's breath. The button-activated mask produces results in 90 minutes and its accuracy is comparable to established nucleic acid-based diagnostic tests such as polymerase chain reactions (PCR). If a person is infected, the mask would generate a fluorescent signal that a handheld fluorometer could detect.
Browse 58 Market Data Tables and 43 Figures spread through 180 Pages and in-depth TOC on “Cell-Free Protein Expression Market”- Global Forecast to 2030, by Product Type (E. coli Cell-free Protein Expression System, Rabbit Reticulocytes Cell-free Protein Expression System, Wheat Germ Cell-free Protein Expression System, Insect Cells Cell-free Protein Expression System, Mammalian Cell-free Protein Expression System, Labelling Tags, and Others {Vectors, yeast cell extracts, among others}), by Expression Mode (Continuous flow Expression, and Batch Expression), by Application (Enzyme Engineering, Protein Labeling, Protein-Protein interaction, Protein Purification, and Others {High Throughput Production, among others}), by End User (Biotechnological Companies, Pharmaceutical Companies, Contract Research Organizations, and Academic/ Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the global Cell-Free Protein Expression Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cell-free-protein-expression-market-1082
Key players operating in market are focusing on adoption of inorganic growth strategies such as partnerships, and others in order to strengthen their position in the market. For instance, in January 2022, Thermo Fisher Scientific Inc., a U.S.-based provider of scientific instrumentation, reagents and consumables announced that it acquired PeproTech, a U.S.-based producer of high quality recombinant cytokines and growth factors for biological research. This acquisition will allow Thermo Fisher Scientific Inc.to expand its cell culture media products portfolio with addition of PeproTech's recombinant and cell-free protein expression portfolio.
Key Takeaways of the Global Cell-Free Protein Expression Market:
- Global Cell-Free Protein Expression Market is expected to exhibit a CAGR of 6.4% over the forecast period, owing to rising strategic business agreements between market players for development of cell-free protein expression products. For instance, in October 2021, Sutro Biopharma, Inc., a U.S.-based clinical-stage drug discovery, development, and manufacturing company that uses cell-free system to create antibodies for treating cancer, entered into an agreement with BioNova Pharmaceuticals Limited (BioNova), a China-based pharmaceutical company.
- As a part of this agreement, BioNova Pharmaceuticals Limited received the exclusive rights to develop and commercialize Sutro Biopharma, Inc’s., STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan. Sutro Biopharma, Inc. will retain the development and commercial rights of STRO-001 globally outside of Greater China, including the U.S. STRO-001 was discovered by using the integrated cell-free protein synthesis platform XpressCF and site-specific conjugation platform XpressCF+ of Sutro Biopharma, Inc.
- Among product type, E. coli Cell-free Protein Expression System segment is expected to account for the largest market share in 2022, owing to rising research and development in the field of E.coli cell-free protein expression. For instance, in May 2019, the Joint Genome Institute Community Science Program and the National Institute of General Medical Sciences (NIGMS) funded a study to build a modular, cell-free platform for the construction and testing of monoterpenoid pathways, using the fragrance and flavouring molecule limonene as a model. In the study, multiple Escherichia coli lysates, each enriched with a single overexpressed pathway enzyme are mixed to construct the full biosynthetic pathway. This study paved the way and suggested that this platform could have future utility as a method for prototyping enzymatic monoterpenoid pathways.
- Key players operating in the global Cell-Free Protein Expression Market include Thermo Fisher Scientific, Inc., Takara Bio, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, CellFree Sciences Co., Ltd., Moderna Therapeutics, Biotechrabbit GmbH, Bioneer Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Daicel Arbor Biosciences Daicel Arbor Biosciences, Profacgen, Creative Biolabs, biotechrabbit, Roche Molecular Systems, Inc., Cusabio Technology LLC, and LenioBio
